Echosens Will Host Phoenix Panel on Metabolic Health
The company will discuss liver disease management and GLP-1 drug costs at the 2026 SIIA National Conference.
Updated on Oct. 8, 2026 in Diabetes
Live Poll
Should your employer prioritize funding for expensive specialty drugs or early disease screening programs?
On October 13, 2026, Echosens will participate in a panel at the SIIA National Conference in Phoenix. The discussion will focus on metabolic health strategies and managing the costs associated with GLP-1 drugs.
Why it matters
Metabolic dysfunction-associated steatohepatitis (MASH) is frequently asymptomatic, making early diagnostic tools essential for identifying patients who may otherwise remain undiagnosed.
FibroScan technology has been featured in over 5,600 peer-reviewed publications and is cited in 220 international guidelines. It offers a non-invasive assessment of liver stiffness and fat for clinical workflows.
The players
Echosens
This company is a medical technology firm based in Westborough, Massachusetts, that specializes in non-invasive liver diagnostics.
Shawn McGinnis
He serves as the Director of Health Systems and Employer Markets at Echosens.
The details
Echosens will showcase the FibroScan diagnostic tool, which facilitates rapid, non-invasive liver assessments. The company provides specific operator training and onboarding to help healthcare systems integrate this technology into routine clinical care.
Timeline
October 13, 2026: The panel at the SIIA National Conference 2026 takes place in Phoenix.
The Big Picture
This panel takes place during the SIIA National Conference 2026, which gathers stakeholders to address evolving health benefit strategies. It follows a pattern set by industry events that prioritize the integration of diagnostic technology into employer-sponsored health plans.
The use of non-invasive tools like FibroScan can streamline diagnosis for patients at risk for metabolic liver conditions. These advancements help providers identify disease earlier, potentially altering treatment plans for those with obesity or type 2 diabetes.
The takeaway
Early screening for metabolic liver disease is increasingly important given the high prevalence of comorbidities among MASH patients. Integrating non-invasive diagnostics into standard physicals may assist in capturing disease before it progresses to advanced stages.
Further reading
Learn more about advancements in metabolic care by visiting our Diabetes section.
More information
For additional technical details and corporate information, visit the Echosens corporate website.
Source note: This article includes information reported by The Manila times.
Live Poll
Should your employer prioritize funding for expensive specialty drugs or early disease screening programs?
